FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313989912> ?p ?o ?g. }

• W4313989912 endingPage "e002742" @default.
• W4313989912 startingPage "e002742" @default.
• W4313989912 abstract "Objective Treatment-refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening condition without evidence-based treatment options. One emerging treatment option for several antibody-mediated autoimmune diseases is the anti-CD38 antibody daratumumab, which depletes autoantibody-secreting plasma cells. Methods We treated two patients with severe life-threatening AAV with renal and pulmonary manifestation despite induction therapy with rituximab and cyclophosphamide with four to eight doses of 1800 mg daratumumab. We followed clinical and immunological responses. Results The first patient with myeloperoxidase-ANCA-positive microscopic polyangiitis had resolution of pneumonitis and pleuritis and stabilisation of kidney function after daratumumab. The second patient with proteinase 3-ANCA-positive granulomatosis with polyangiitis, diffuse alveolar haemorrhage necessitating extracorporeal membrane oxygenation (ECMO) and acute kidney failure, requiring kidney replacement therapy, was weaned off ECMO, mechanical ventilation and dialysis and discharged home after daratumumab. Clinical improvement was paralleled by a strong reduction in serum ANCA levels as well as total IgG, indicating depletion of plasma cells. Apart from the depletion of CD38 + natural killer cells, blood leucocyte levels were not notably influenced by daratumumab. Only mild adverse events, such as hypogammaglobulinaemia and an upper respiratory tract infection occurred. Conclusion Daratumumab was safe and effective in inducing remission in two patients with severe treatment-refractory AAV, warranting prospective clinical trials to establish safety and efficacy." @default.
• W4313989912 created "2023-01-10" @default.
• W4313989912 creator A5002084661 @default.
• W4313989912 creator A5009874236 @default.
• W4313989912 creator A5018971440 @default.
• W4313989912 creator A5025207344 @default.
• W4313989912 creator A5026938459 @default.
• W4313989912 creator A5051985691 @default.
• W4313989912 creator A5077252858 @default.
• W4313989912 creator A5084248314 @default.
• W4313989912 creator A5089923693 @default.
• W4313989912 date "2023-01-01" @default.
• W4313989912 modified "2023-10-15" @default.
• W4313989912 title "Daratumumab for the treatment of refractory ANCA-associated vasculitis" @default.
• W4313989912 cites W137802152 @default.
• W4313989912 cites W1970860090 @default.
• W4313989912 cites W2063340779 @default.
• W4313989912 cites W2110524090 @default.
• W4313989912 cites W2146853551 @default.
• W4313989912 cites W2147350349 @default.
• W4313989912 cites W2289022229 @default.
• W4313989912 cites W2746807212 @default.
• W4313989912 cites W2765695907 @default.
• W4313989912 cites W2900280452 @default.
• W4313989912 cites W2980839950 @default.
• W4313989912 cites W3086471819 @default.
• W4313989912 cites W3134697946 @default.
• W4313989912 cites W3146742891 @default.
• W4313989912 cites W4210402133 @default.
• W4313989912 cites W4220732683 @default.
• W4313989912 cites W4225410665 @default.
• W4313989912 doi "https://doi.org/10.1136/rmdopen-2022-002742" @default.
• W4313989912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36627149" @default.
• W4313989912 hasPublicationYear "2023" @default.
• W4313989912 type Work @default.
• W4313989912 citedByCount "4" @default.
• W4313989912 countsByYear W43139899122023 @default.
• W4313989912 crossrefType "journal-article" @default.
• W4313989912 hasAuthorship W4313989912A5002084661 @default.
• W4313989912 hasAuthorship W4313989912A5009874236 @default.
• W4313989912 hasAuthorship W4313989912A5018971440 @default.
• W4313989912 hasAuthorship W4313989912A5025207344 @default.
• W4313989912 hasAuthorship W4313989912A5026938459 @default.
• W4313989912 hasAuthorship W4313989912A5051985691 @default.
• W4313989912 hasAuthorship W4313989912A5077252858 @default.
• W4313989912 hasAuthorship W4313989912A5084248314 @default.
• W4313989912 hasAuthorship W4313989912A5089923693 @default.
• W4313989912 hasBestOaLocation W43139899121 @default.
• W4313989912 hasConcept C121332964 @default.
• W4313989912 hasConcept C126322002 @default.
• W4313989912 hasConcept C142424586 @default.
• W4313989912 hasConcept C159654299 @default.
• W4313989912 hasConcept C163764329 @default.
• W4313989912 hasConcept C203014093 @default.
• W4313989912 hasConcept C21194631 @default.
• W4313989912 hasConcept C24040308 @default.
• W4313989912 hasConcept C2776015282 @default.
• W4313989912 hasConcept C2776694085 @default.
• W4313989912 hasConcept C2776755627 @default.
• W4313989912 hasConcept C2778910314 @default.
• W4313989912 hasConcept C2779134260 @default.
• W4313989912 hasConcept C2779978075 @default.
• W4313989912 hasConcept C2780653079 @default.
• W4313989912 hasConcept C2781119759 @default.
• W4313989912 hasConcept C2781229154 @default.
• W4313989912 hasConcept C542903549 @default.
• W4313989912 hasConcept C71924100 @default.
• W4313989912 hasConcept C87355193 @default.
• W4313989912 hasConcept C90924648 @default.
• W4313989912 hasConceptScore W4313989912C121332964 @default.
• W4313989912 hasConceptScore W4313989912C126322002 @default.
• W4313989912 hasConceptScore W4313989912C142424586 @default.
• W4313989912 hasConceptScore W4313989912C159654299 @default.
• W4313989912 hasConceptScore W4313989912C163764329 @default.
• W4313989912 hasConceptScore W4313989912C203014093 @default.
• W4313989912 hasConceptScore W4313989912C21194631 @default.
• W4313989912 hasConceptScore W4313989912C24040308 @default.
• W4313989912 hasConceptScore W4313989912C2776015282 @default.
• W4313989912 hasConceptScore W4313989912C2776694085 @default.
• W4313989912 hasConceptScore W4313989912C2776755627 @default.
• W4313989912 hasConceptScore W4313989912C2778910314 @default.
• W4313989912 hasConceptScore W4313989912C2779134260 @default.
• W4313989912 hasConceptScore W4313989912C2779978075 @default.
• W4313989912 hasConceptScore W4313989912C2780653079 @default.
• W4313989912 hasConceptScore W4313989912C2781119759 @default.
• W4313989912 hasConceptScore W4313989912C2781229154 @default.
• W4313989912 hasConceptScore W4313989912C542903549 @default.
• W4313989912 hasConceptScore W4313989912C71924100 @default.
• W4313989912 hasConceptScore W4313989912C87355193 @default.
• W4313989912 hasConceptScore W4313989912C90924648 @default.
• W4313989912 hasFunder F4320320879 @default.
• W4313989912 hasIssue "1" @default.
• W4313989912 hasLocation W43139899121 @default.
• W4313989912 hasLocation W43139899122 @default.
• W4313989912 hasLocation W43139899123 @default.
• W4313989912 hasLocation W43139899124 @default.
• W4313989912 hasOpenAccess W4313989912 @default.
• W4313989912 hasPrimaryLocation W43139899121 @default.

• next